Showing accelerated innovation and strong 225% revenue growth YANTAI, China, March 27, 2023 /PRNewswire/ -- Boan Biotech (6955.HK) today announced its 2022 financial results and recent business developments. 2022 business highlights Eye-catching performance of two marketed products Boan Biotech's first drug Boyounuo (bevacizumab injection, a biosimilar to Avastin®) is used for the treatment of multiple cancers. Sales grew rapidly...